Short answer
iRhythm Holdings, Inc. (IRTC) filed its Q3 2025 10-Q quarterly report on Oct 30, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $193M (up 30.7% year over year) with net income of −$5M.
Q3 2025 key financials · XBRL
- Revenue
- $193M
- +30.7% YoY · +3.3% QoQ
- Net income
- −$5M
- +88.7% YoY · +63.3% QoQ
- Operating margin
- -4.4%
- Gross margin
- 71.1%
- EPS (diluted)
- −$0.16
- +89.1% YoY · +63.6% QoQ
Source: XBRL data from the iRhythm Holdings, Inc. (IRTC) Q3 2025 10-Q on SEC EDGAR. USD.
iRhythm Holdings, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No new or updated risk factors disclosed in this 10-Q vs prior 10-K
- Regulatory risk: ongoing dependence on FDA device clearance and evolving healthcare reimbursement policies
- Operational risk: competitive pressure in arrhythmia diagnostic devices market impacting near-term sales growth
- Financial risk: liquidity strong with $150M cash and no debt maturities until 2027; minimal currency exposure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other iRhythm Holdings, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.